We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COVID-19 Variants Raise Concern about Eli Lilly’s Antibody Treatment
COVID-19 Variants Raise Concern about Eli Lilly’s Antibody Treatment
Eli Lilly CEO David Ricks has expressed concern that the new variant of the coronavirus that causes COVID-19 first reported in South Africa might be resistant to the company’s antibody treatment bamlanivimab.